本文選題：MicroRNA + miR-17-5p�。� 參考：《浙江大學(xué)》2016年博士論文

【摘要】：背景：胃癌是全球腫瘤致死主要原因之一,在我國是僅次于肺癌死亡率排名第二的惡性腫瘤�；熓俏赴┲委煹闹匾侄沃弧Ｎ赴┘�(xì)胞對(duì)化療藥物產(chǎn)生耐藥性導(dǎo)致胃癌化療失敗的主要原因之一。胃癌患者如果對(duì)化療出現(xiàn)耐藥情況,預(yù)后較差,所以明確胃癌細(xì)胞產(chǎn)生耐藥的分子機(jī)制十分重要。microRNA (miRNA)是內(nèi)源性非編碼小RNA分子,它們通過調(diào)節(jié)靶基因mRNA的翻譯或降解而起到調(diào)節(jié)基因的作用。miRNA在腫瘤中通過對(duì)下游靶基因的調(diào)節(jié),對(duì)其發(fā)生與發(fā)展起到至關(guān)重要的作用。近年來的研究證實(shí)了miRNA在抗腫瘤藥物的敏感性和耐藥性中起了重要作用。以特定的miRNA為治療靶點(diǎn),通過比較miRNA表達(dá)譜,與腫瘤細(xì)胞耐藥性密切相關(guān)的特定miRNA將被識(shí)別,這可能為新的靶向治療方案開辟途徑,從而改善治療效果。然而miRNA影響胃癌細(xì)胞耐藥性的作用機(jī)制并不明了。因此準(zhǔn)確尋找對(duì)胃癌耐藥細(xì)胞影響較大的miRNA并探討其作用機(jī)制,成為亟待解決的重要問題。本研究擬在兩種耐藥胃癌細(xì)胞SGC7901/DDP和BGC823/5-FU中篩選出與親本細(xì)胞表達(dá)差異較大的miRNA,并深入探討其對(duì)細(xì)胞耐藥性的影響作用及其作用機(jī)制。目的：在兩種耐藥胃癌細(xì)胞SGC7901/DDP和BGC823/5-FU中分析miRNA表達(dá)譜,篩選耐藥相關(guān)特異性miRNA;研究耐藥相關(guān)miRNA對(duì)胃癌細(xì)胞株耐藥性的影響；尋找潛在靶點(diǎn),探討其作用分子機(jī)制,以期為新的靶向治療方案開辟途徑。方法：采用基因芯片技術(shù)分別檢測(cè)胃癌細(xì)胞SGC7901及其耐藥細(xì)胞SGC7901/DDP、胃癌細(xì)胞BGC823及其耐藥細(xì)胞BGC823/5-FU的miRNA的表達(dá)差異情況,尋找在兩株胃癌耐藥細(xì)胞中與親本細(xì)胞之間尋找表達(dá)差異較大的miRNA,并采用實(shí)時(shí)定量PCR方法進(jìn)行驗(yàn)證。通過體外轉(zhuǎn)染抑制序列anti-miR-17-5p序列下調(diào)細(xì)胞中的miR-17-5p表達(dá),CCK-8法分析轉(zhuǎn)染后細(xì)胞對(duì)長(zhǎng)春新堿、阿霉素、5-氟尿嘧啶和順鉑的藥物敏感性變化。運(yùn)用生物信息學(xué)工具PicTar和Miranda algorithms預(yù)測(cè)miR-17-5p的靶基因。構(gòu)建熒光素酶報(bào)告質(zhì)粒pGL3-p21-3'-UTR驗(yàn)證miR-17-5p與預(yù)測(cè)靶基因p21的相互作用。通過WesternBlot方法檢測(cè)胃癌耐藥細(xì)胞株SGC7901/DDP和BGC823/5-FU中miR-17-5p對(duì)p21的調(diào)控作用。流式細(xì)胞術(shù)檢測(cè)miR-17-5p對(duì)胃癌耐藥細(xì)胞株SGC7901/DDP和BGC823/5-FU細(xì)胞凋亡和細(xì)胞周期的影響。細(xì)胞計(jì)數(shù)的方法檢測(cè)miR-17-5p對(duì)胃癌耐藥細(xì)胞株SGC7901/DDP和BGC823/5-FU細(xì)胞生長(zhǎng)的影響。結(jié)果：基因芯片分析結(jié)果顯示：與SGC7901細(xì)胞相比,SGC7901/DDP細(xì)胞中miR-17-5p的表達(dá)明顯上調(diào)(P0.01); BGC823/5-FU細(xì)胞中miR-17-5p的表達(dá)較BGC823細(xì)胞明顯上調(diào)(P0.01)。實(shí)時(shí)定量熒光PCR分析結(jié)果顯示：耐藥SGC7901/DDP與BGC823/5-FU細(xì)胞中miR-17-5p表達(dá)水平均顯著上調(diào)(P0.01)。抑制SGC7901/DDP細(xì)胞和BGC823/5-FU細(xì)胞中miR-17-5p表達(dá)可有效提高細(xì)胞對(duì)順鉑、阿霉素、長(zhǎng)春新堿和5-FU的藥物敏感性(P0.05)。根據(jù)生物信息學(xué)工具的預(yù)測(cè)miR-17-5p的靶基因可能為p21。對(duì)p21基因3’非編碼區(qū)報(bào)告質(zhì)粒熒光素酶活性測(cè)定顯示miR-17-5p可顯著降低pGL3-p21-3'-UTR相對(duì)熒光酶活性(P0.05)。在胃癌耐藥細(xì)胞SGC7901/DDP和BGC823/5-FU中抑制miR-17-5p表達(dá)可明顯增加p21蛋白的表達(dá)(P0.05)。抑制miR-17-5p表達(dá)還可抑制胃癌耐藥細(xì)胞SGC7901/DDP和BGC823/5-FU的生長(zhǎng)(P0.05),并誘導(dǎo)細(xì)胞凋亡(P0.05)。在胃癌耐藥細(xì)胞SGC7901/DDP和BGC823/5-FU中抑制miR-17-5p表達(dá)可使G1期細(xì)胞明顯減少,而S期細(xì)胞明顯增多,引起細(xì)胞周期G1-S期阻滯(P0.05)。結(jié)論：與親代非耐藥胃癌細(xì)胞相比,miR-17-5p在耐藥細(xì)胞SGC7901/DDP和BGC823/5-FU細(xì)胞中表達(dá)顯著增高。抑制miR-17-5p表達(dá)可明顯改善胃癌細(xì)胞耐藥性,同時(shí)抑制胃癌耐藥細(xì)胞的生長(zhǎng)活力、誘導(dǎo)細(xì)胞凋亡病引起細(xì)胞周期G1-S期阻滯。究其分子機(jī)制,miR-17-5p可能是通過調(diào)控其靶基因p21的表達(dá)影響胃癌耐藥細(xì)胞的凋亡和增殖。本研究發(fā)現(xiàn)miR-17-5p的表達(dá)可明顯降低胃癌細(xì)胞的耐藥性,為臨床上克服胃癌化療時(shí)細(xì)胞耐藥性難題提供理論支持和新的分子靶標(biāo)。
[Abstract]:Background: gastric cancer is one of the leading causes of death in the world, and it is the second most malignant tumor next to lung cancer in our country. Chemotherapy is one of the most important methods for the treatment of gastric cancer. The drug resistance of gastric cancer cells to chemotherapy leads to one of the main reasons for the failure of chemotherapy for gastric cancer. .microRNA (miRNA) is an endogenous non coding small RNA molecule, which is an endogenous non coding small RNA molecule. They play the role of regulating gene by regulating the translation or degradation of the target gene mRNA, and.MiRNA plays an important role in the development and development of the tumor by regulating the target gene in the downstream. Recent studies have demonstrated that miRNA plays an important role in the sensitivity and resistance of antitumor drugs. Specific miRNA as the target of treatment, specific miRNA, which is closely related to the drug resistance of tumor cells, will be identified by comparing miRNA expression profiles. This may open up a way for the new target therapy and improve the therapeutic effect. However, the mechanism of the effect of miRNA on the drug resistance of gastric cancer cells is not clear. Therefore, it is an important problem to find out exactly how to find the miRNA and explore its mechanism of action to the drug resistant cells of gastric cancer. This study is to screen out the MI of two kinds of drug-resistant gastric cancer cells, SGC7901/DDP and BGC823/5-FU, which are different from those of the parent cells. RNA, and explore its effect on cell resistance and its mechanism of action. Objective: to analyze the miRNA expression profiles in two resistant gastric cancer cells, SGC7901/DDP and BGC823/5-FU, to screen resistance related specific miRNA, to study the response of drug resistance related miRNA to the drug resistance of gastric cancer cell lines, to search for potential targets and to explore the molecular mechanism of its action. System, in order to open up a new approach to target treatment. Methods: gene chip technology was used to detect the differential expression of miRNA in gastric cancer cell SGC7901 and its resistant cell SGC7901/DDP, gastric cancer cell BGC823 and its drug-resistant cells BGC823/5-FU, and to find the difference of expression between two gastric cancer cells and parental cells. Large miRNA, and verified by real-time quantitative PCR method. Down regulation of miR-17-5p expression in cells through in vitro transfection inhibition sequence anti-miR-17-5p sequence and CCK-8 assay for changes in drug sensitivity of transfected cells to vincristine, adriamycin, 5- fluorouracil and cisplatin. Use bioinformatics tool PicTar and Miranda algorithms preconditioning. The target gene of miR-17-5p was measured. A luciferase reporter plasmid pGL3-p21-3'-UTR was constructed to verify the interaction between miR-17-5p and the predicted target gene p21. The regulation of miR-17-5p on p21 in gastric cancer cell line SGC7901/DDP and BGC823/5-FU was detected by WesternBlot. Flow cytometry was used to detect miR-17-5p to the drug resistant cell line of gastric cancer. The effect of BGC823/5-FU cell apoptosis and cell cycle. Cell count method was used to detect the effect of miR-17-5p on the growth of SGC7901/DDP and BGC823/5-FU cells in gastric cancer cell lines. Results: gene chip analysis showed that the expression of miR-17-5p in SGC7901/DDP cells was obviously up regulated compared with SGC7901 cells (P0.01) and BGC823/5-FU cells in BGC823/5-FU cells. The expression of miR-17-5p was significantly higher than that of BGC823 cells (P0.01). Real-time quantitative fluorescence PCR analysis showed that the expression level of miR-17-5p in drug-resistant SGC7901/DDP and BGC823/5-FU cells increased significantly (P0.01). Inhibition of miR-17-5p expression in SGC7901/DDP and BGC823/5-FU cells could improve cells to cisplatin, adriamycin, vincristine and 5-F. U's drug sensitivity (P0.05). According to bioinformatics tools, the target gene for miR-17-5p may be p21. to the p21 gene 3 'non coding region report plasmid luciferase activity determination that miR-17-5p can significantly reduce the pGL3-p21-3'-UTR relative fluorescent enzyme activity (P0.05). Inhibition of miR-17-5p in gastric cancer resistant cells SGC7901/DDP and BGC823/5-FU is miR-17-5p. Expression can significantly increase the expression of p21 protein (P0.05). Inhibition of miR-17-5p expression also inhibits the growth of SGC7901/DDP and BGC823/5-FU in gastric cancer cells (P0.05) and induces apoptosis (P0.05). Inhibition of miR-17-5p expression in the SGC7901/DDP and BGC823/5-FU of gastric cancer cells can significantly reduce G1 phase cells, while S cells increase significantly. Cell cycle G1-S phase block (P0.05). Conclusion: the expression of miR-17-5p in the SGC7901/DDP and BGC823/5-FU cells of drug resistant cells is significantly higher than that of non drug resistant gastric cancer cells. Inhibition of miR-17-5p expression can obviously improve the drug resistance of gastric cancer cells, inhibit the growth of gastric cancer cells and induce cell apoptosis caused by cell cycle. Phase G1-S phase block. The molecular mechanism of miR-17-5p may be to influence the apoptosis and proliferation of gastric cancer cells by regulating the expression of its target gene p21. This study found that the expression of miR-17-5p can significantly reduce the drug resistance of gastric cancer cells and provide theoretical support and new molecular target for overcoming the problem of cell resistance in gastric cancer chemotherapy.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R735.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 吳延;蔣義國;;miR-17-5p與反式-7,8-二羥-9,10-環(huán)氧苯并芘誘導(dǎo)轉(zhuǎn)化的人支氣管上皮細(xì)胞生物學(xué)特性的關(guān)系研究[J];環(huán)境與健康雜志;2010年05期

2 王偉;李覃;李成文;朱鳴陽;韓光;;尿液miR-17-5p檢測(cè)對(duì)膀胱癌的診斷價(jià)值[J];空軍醫(yī)學(xué)雜志;2013年03期

3 任海林;李曉娜;陳國俊;侯智;索吉明;孫巖;張春霆;王健;;膀胱癌石蠟包埋組織中miR-17-5p的表達(dá)與復(fù)發(fā)的相關(guān)性[J];實(shí)用醫(yī)學(xué)雜志;2013年19期

4 ;[J];;年期

相關(guān)博士學(xué)位論文 前1條

1 王子薇;胃癌耐藥相關(guān)microRNA表達(dá)譜及miR-17-5p逆轉(zhuǎn)胃癌細(xì)胞耐藥作用的研究[D];浙江大學(xué);2016年

，

本文編號(hào)：2066619